Patents by Inventor Akshay K. Vaishnaw

Akshay K. Vaishnaw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating or preventing sclerotic disorders using CD-2 binding agents
    Patent number: 7858095
    Abstract: Methods and compositions for treating or preventing fibrotic disorders, e.g., sclerotic disorders, for example scleroderma, using CD2-binding agents, e.g., LFA-3/IgG fusion polypeptides or LFA-3-binding agents, are provided.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: December 28, 2010
    Assignee: Astellas US LLC
    Inventor: Akshay K. Vaishnaw
  • Method for treating or preventing sclerotic disorders using cd-2 binding agents
    Publication number: 20040265305
    Abstract: Methods and compositions for treating or preventing fibrotic disorders, e.g., sclerotic disorders, for example scleroderma, using CD2-binding agents, e.g., LFA-3/IgG fusion polypeptides or LFA-3-binding agents, are provided.
    Type: Application
    Filed: June 21, 2004
    Publication date: December 30, 2004
    Inventor: Akshay K. Vaishnaw
  • Methods for treating or preventing skin disorders using cd2-binding agents
    Publication number: 20040170635
    Abstract: Methods for treating or preventing an epidermal or dermal disorder, e.g., psoriasis, using a CD2-binding agent, e.g., an inhibitor of the CD2/LFA-3 interaction (e.g., an LFA-3/IgG fusion polypeptide), in combination with an auxiliary agent, e.g., UVB irradiation, are disclosed.
    Type: Application
    Filed: February 10, 2004
    Publication date: September 2, 2004
    Inventors: Akshay K. Vaishnaw, Kevin D. Cooper, Daniel Schrager, Thomas S. Mccormick
  • Methods for treating or preventing skin disorders using CD2-binding agents
    Publication number: 20030185824
    Abstract: Methods for treating or preventing an epidermal or dermal disorder, e.g., psoriasis, using a CD2-binding agent, e.g., an inhibitor of the CD2/LFA-3 interaction (e.g., an LFA-3/IgG fusion polypeptide), in combination with an auxiliary agent, e.g., UVB irradiation, are disclosed.
    Type: Application
    Filed: December 26, 2002
    Publication date: October 2, 2003
    Inventors: Akshay K. Vaishnaw, Kevin D. Cooper, Daniel Shrager, Thomas S. McCormick
  • Use of a CD40:CD154 binding interruptor to treat immunological complications of the eye
    Publication number: 20030027744
    Abstract: The invention relates generally to the treatment and inhibition of immunological complications of the eye. Such complications include unwanted immune responses resulting in an ocular inflammatory disease, resulting from a corneal or retinal graft transplantation or resulting from ocular angiogenesis, particularly ocular neovascularization. The invention relates in particular to the inhibition, treatment, or reversal of immune-system driven rejection of grafted corneal or retinal tissue or cells in a recipient host and to the treatment or inhibition of ocular inflammatory disease or ocular neovascularization in a host.
    Type: Application
    Filed: April 18, 2002
    Publication date: February 6, 2003
    Inventors: M. Reza Dana, Akshay K. Vaishnaw, Linda C. Burkly, Roy Lobb, Burt Adelman